stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) EV/FCF
As of 6 November 2026, AbCellera Biologics Inc. (ABCL) trades at a EV/FCF of −25.0×. Over the past ten years it has ranged from −32.3× (September 2026) to 983× (February 2021); the current reading is higher than 2% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −2.6× | — |
| FY2024 | −1.1× | — |
| FY2023 | −7.1× | — |
| FY2022 | 8.8× | (48.92%) |
| FY2021 | 17.2× | (97.63%) |
| FY2020 | 725× | (3.00%) |
| FY2019 | 748× | 0.00% |
| FY2018 | 748× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −15.0× | — |
| Mar 2026 | −2.8× | — |
| Dec 2025 | −2.6× | — |
| Sep 2025 | −6.3× | — |
| 22 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | −23.6× |
| ABCL AbCellera Biologics Inc. | −23.4× |
| ACAD ACADIA Pharmaceuticals Inc. compare | −23.3× |
| TNGX Tango Therapeutics, Inc. compare | −15.0× |
| IOVA Iovance Biotherapeutics, Inc. compare | −14.9× |
| RLAY Relay Therapeutics, Inc. compare | −12.0× |
| XENE Xenon Pharmaceuticals Inc. compare | −8.5× |
| PBLS Parabilis Medicines, Inc. compare | 2.6× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 76.5× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement